| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| CDMO业务(元) | 523,612,852.73 | 1,033,790,319.64 | 560,377,930.18 |
| 肝素钠(原料药)(元) | 452,316,621.69 | 1,069,311,038.42 | 747,769,178.46 |
| 肝素钠制剂(元) | 1,776,729,260.83 | 2,986,074,622.21 | 1,453,516,215.94 |
| 其他(元) | 64,688,436.92 | 191,537,430.53 | 75,737,582.29 |
| 营业成本(元) | |||
| CDMO业务(元) | 332,086,591.47 | 663,338,983.47 | 385,815,055.84 |
| 肝素钠(原料药)(元) | 344,586,251.82 | 755,327,583.29 | 475,225,879.55 |
| 肝素钠制剂(元) | 1,225,137,748.01 | 1,982,620,666.75 | 933,261,498.13 |
| 其他(元) | 37,547,499.98 | 123,271,013.59 | 54,842,815.23 |
| 毛利(元) | |||
| CDMO业务(元) | 191,526,261.26 | 370,451,336.17 | 174,562,874.34 |
| 肝素钠(原料药)(元) | 107,730,369.87 | 313,983,455.13 | 272,543,298.91 |
| 肝素钠制剂(元) | 551,591,512.82 | 1,003,453,955.46 | 520,254,717.81 |
| 其他(元) | 27,140,936.94 | 68,266,416.94 | 20,894,767.06 |
| 毛利率(%) | |||
| CDMO业务(%) | 36.58 | 35.83 | 31.15 |
| 肝素钠(原料药)(%) | 23.82 | 29.36 | 36.45 |
| 肝素钠制剂(%) | 31.05 | 33.60 | 35.79 |
| 其他(%) | 41.96 | 35.64 | 27.59 |
| 收入构成(%) | |||
| CDMO业务(%) | 18.59 | 19.58 | 19.75 |
| 肝素钠(原料药)(%) | 16.05 | 20.25 | 26.35 |
| 肝素钠制剂(%) | 63.06 | 56.55 | 51.23 |
| 其他(%) | 2.30 | 3.63 | 2.67 |
| 毛利构成(%) | |||
| CDMO业务(%) | 21.81 | 21.09 | 17.66 |
| 肝素钠(原料药)(%) | 12.27 | 17.88 | 27.58 |
| 肝素钠制剂(%) | 62.82 | 57.14 | 52.64 |
| 其他(%) | 3.09 | 3.89 | 2.11 |